# KPV: The Anti-Inflammatory Fragment With Zero Human Trials > KPV: Research Overview — bigfootpeptides — A cited literature summary of KPV, the alpha-MSH-derived anti-inflammatory tripeptide studied in gut-inflammation models. Mechanism, findings, and the honest evidence gap: zero human trials. **04 / RECOVERY & TISSUE REPAIR** A three-amino-acid piece of a pigment hormone, entirely mouse-and-cell-dish evidence so far, but a delivery story that keeps advancing. ## The short version KPV is a tiny, three-amino-acid peptide (lysine-proline-valine) that's actually a fragment of a much larger, more familiar hormone: alpha-melanocyte-stimulating hormone (alpha-MSH), the one that drives skin pigmentation. KPV is the tail end of that hormone — and it keeps the anti-inflammatory activity while dropping the pigment-darkening effect entirely, which is why researchers study it on its own. Its research niche is gut inflammation. KPV gets pulled directly into intestinal cells through a transporter normally used to absorb digested protein fragments, and once inside, it dampens the same inflammatory signaling (NF-kB) that drives conditions like colitis in animal models. Here's the honest limitation: there are no published human clinical trials of KPV at all. Every result on this page comes from mice, rats, or cells in a dish. Nothing here should be read as a demonstrated human effect. ## What it is KPV (L-lysyl-L-prolyl-L-valine, Lys-Pro-Val) is a linear tripeptide, molecular formula C16H30N4O4, corresponding to residues 11-13 — the C-terminal end — of alpha-MSH. It's sometimes labeled alpha-MSH(11-13) in older literature. Because it's such a small fragment, it retains only part of the parent hormone's activity: it keeps the anti-inflammatory signaling but loses the pigmentary, melanogenic, effect that makes alpha-MSH relevant to tanning and skin-color research. That split — anti-inflammatory without pigment effect — is the entire reason KPV exists as a distinct research subject rather than just being described as a piece of alpha-MSH. ## How it works KPV's anti-inflammatory action centers on two related signaling systems: it suppresses NF-kB, one of the body's master switches for turning on inflammatory genes, and it dampens MAP-kinase signaling, another pathway cells use to coordinate an inflammatory response. The practical effect in cell studies is reduced production of pro-inflammatory cytokines, the signaling proteins that recruit and activate immune cells [20]. In the gut specifically, KPV has a delivery advantage most peptides don't: it's small enough to be taken up directly into intestinal epithelial cells through PepT1, a transporter the gut normally uses to absorb small protein fragments from digested food. PepT1 is upregulated in inflamed intestinal tissue, which means KPV may get preferentially delivered exactly where gut inflammation is worst [20]. ## What the research shows All five studies behind KPV's research profile are in mice, rats, or human cells in a dish — none is a human clinical trial. A 2024 study built a nanodrug that co-assembled KPV with the immunosuppressant FK506, targeted to PepT1, and tested it in mice with both acute and chronic colitis; the combination improved outcomes in both models, restored tight-junction proteins in the gut lining, and lowered inflammatory cytokines more than either drug given alone [18]. A 2017 study took a different delivery approach — oral, hyaluronic-acid-coated nanoparticles carrying KPV inside a hydrogel — and found it reduced colitis severity and downregulated the inflammatory cytokine TNF-alpha more effectively than non-targeted delivery in mice [19]. The foundational mechanistic work is a 2008 Gastroenterology study showing KPV is transported into human intestinal cell lines via PepT1, and that nanomolar concentrations of KPV reduce NF-kB and MAP-kinase activation and cytokine secretion in both epithelial and immune cells, with oral KPV also reducing colitis severity in two different mouse models [20]. A companion 2008 study found KPV-treated mice recovered from colitis earlier, with lower inflammatory-marker activity and reduced inflammatory infiltrate, and notably the effect held even in mice genetically missing the main melanocortin receptor, indicating KPV works through a pathway independent of that receptor [21]. A broader 2008 review situates KPV within a family of alpha-MSH-derived tripeptides shown to have protective effects across a wide range of animal inflammatory models — fever, dermatitis, vasculitis, fibrosis, eye, gut, brain, airway, joint, and organ-injury models — while explicitly distinguishing KPV as the anti-inflammatory option that skips the pigment effect [22]. ## Reported effects, cautions & safety KPV doesn't have the community-forum track record that BPC-157 or TB-500 do on this site, and that's the honest headline for this section: there are no published human clinical trials of KPV for any purpose, and no compiled reports of anecdotal use to draw on either — the entire evidence base is mouse, rat, and cell-culture research, mostly in models of colitis. That's unusual among the seven compounds tracked here, and worth taking seriously rather than glossing over. A few cautions follow directly from that gap. KPV is a small, peptidase-labile tripeptide, meaning ordinary enzymes in the body can break it down quickly, and no validated human pharmacokinetic data exist; a large share of current research effort is aimed at formulation work just to keep it intact long enough to act. Although KPV derives from alpha-MSH, it should not be confused with melanocortin agonists marketed for tanning or pigmentation — KPV's defining feature in the literature is anti-inflammatory action without the pigment effect. It is not approved as a medicine or dietary supplement in any major jurisdiction, and is sold strictly as a research chemical for laboratory use. ## Where it fits in Recovery & Tissue Repair KPV supplies the anti-inflammatory arm of [KLOW](/klow), the four-peptide blend that adds it to BPC-157, TB-500, and GHK-Cu specifically to cover inflammation-suppression alongside vascular repair, cell migration, and matrix building. It doesn't appear in [Wolverine](/wolverine) or [GLOW](/glow), both of which skip the inflammation-specific ingredient. Because KPV has the thinnest evidence base of any compound on this site — animal and cell data only, no human trials — it's also the clearest test case for how far a mechanism can be trusted before it's actually been tried in people. See the [full comparison](/compare). --- This is a reporter's notebook on repair-peptide research, not a clinic or a supplier — every claim here is tracked to its source, and every source is checked before it's trusted.